{"id":"csa-rapamune-cs","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Gingival hyperplasia"}]},"_chembl":{"chemblId":"CHEMBL1950108","moleculeType":"Small molecule","molecularWeight":"1599.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine A (CsA) inhibits calcineurin, blocking T-cell receptor signaling and IL-2 production. Rapamune (sirolimus) inhibits mTOR, preventing T-cell proliferation and differentiation. Corticosteroids (CS) provide broad immunosuppression by reducing inflammatory cytokine production and immune cell activation. Together, these agents target multiple pathways in the immune response to prevent allograft rejection.","oneSentence":"This triple immunosuppressive regimen combines calcineurin inhibition, mTOR inhibition, and corticosteroid activity to prevent organ rejection by suppressing T-cell activation and proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:38.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (renal, cardiac, hepatic transplantation)"}]},"trialDetails":[{"nctId":"NCT02864706","phase":"PHASE4","title":"SCHEDULE Follow Up Visit 5-7 yr","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-01-18","conditions":"Heart Transplantation","enrollment":95},{"nctId":"NCT01601821","phase":"PHASE4","title":"Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-04","conditions":"Inflammation","enrollment":245},{"nctId":"NCT01266148","phase":"PHASE4","title":"SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Renal Function and Chronic Allograft Vasculopathy","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"CsA+Rapamune+CS","genericName":"CsA+Rapamune+CS","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive regimen combines calcineurin inhibition, mTOR inhibition, and corticosteroid activity to prevent organ rejection by suppressing T-cell activation and proliferation. Used for Organ transplant rejection prophylaxis (renal, cardiac, hepatic transplantation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}